ISPOR SPONSORING SESSION AT DIA 2016 THIS JUNE

Published Apr 5, 2016
ANNOUNCEMENT

SOCIETY’S PRESIDENT-ELECT, LOU GARRISON, LEADING WORKSHOP

Princeton, NJ—April 5, 2016—The International Society for Pharmacoeconomics and Outcomes Research (ISPOR) is attending and contributing to the Drug Information Association (DIA) Annual Meeting being held June 26-30, 2016 in Philadelphia, PA, USA.  ISPOR will be sponsoring a preconference workshop on Sunday, June 26 at DIA 2016. ISPOR President-Elect Lou Garrison, PhD will be one of the instructors for the half-day session entitled, The Evolving Role of Payers in Drug Development: Pricing, Pharmacoeconomics, and Health Technology Assessment. ISPOR is offering this preconference tutorial at this event to provide expanded access to educational resources as part of its mission to promote health economics and outcomes research (HEOR) excellence to improve decision making for health globally. For additional information, please contact Betsy Lane, director, chief marketing and communications officer at BLane@ispor.org or 609-586-4981 x112.

###

Related Stories

New Research Collection Reveals How Artificial Intelligence Is Reshaping Health Economics

Nov 6, 2025

The PhRMA Foundation and ISPOR announced the publication of a special themed section of research papers that explores the dynamic intersection of artificial intelligence (AI) and health economics and outcomes research (HEOR).

ISPOR Announces 2025 Health Economics and Outcomes Research Award Honorees

Oct 20, 2025

ISPOR announced the recipients of its 2025 Health Economics and Outcomes Research (HEOR) Scientific and Leadership Awards. ISPOR Scientific Awards are designed to foster and recognize excellence and outstanding achievement in HEOR and its Leadership Awards recognize excellence and outstanding leadership in the field.

The Ozempic Paradox: How Spending Billions on Weight-Loss Drug Would Actually Reduce Overall Medicare Costs

Oct 14, 2025

Value in Health, the official journal of ISPOR—The Professional Society for Health Economics and Outcomes Research, announced today the publication of a landmark study by researchers at the University of Washington, Curta, Inc, and the University of North Carolina showing that broad Medicare coverage of semaglutide in diabetes, obesity, and liver disease could generate significant cost savings while delivering substantial health benefits to beneficiaries. The report, “Comprehensive Access to Semaglutide: Clinical and Economic Implications for Medicare,” was published in the October 2025 issue of Value in Health.
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×